1. Postal Savings Bank announced its 2025 interim profit distribution plan, featuring a cash dividend of RMB 1.23 per share (tax inclusive), totaling approximately RMB 14.772 billion. The A-share cash dividend amounts to RMB 12.329 billion. The record date is set for January 9, 2026, with the ex-dividend date and cash dividend payment date both scheduled for January 12, 2026.
2. CICT Mobile announced that shareholders China Development Bank Manufacturing Transformation and Upgrading Fund and its concerted actor, CDB Capital, plan to reduce their holdings by no more than 1% of the company's total shares. The减持, totaling no more than 34.1875 million shares, will be conducted through集中竞价trading over a three-month period starting 15 trading days after the announcement disclosure, specifically from January 28, 2026, to April 27, 2026. The selling price will be determined by the market price.
3. Defu Technology announced that its wholly-owned subsidiary, Defu Sales, has signed a Letter of Intent for High-End Copper Foil Cooperation with a leading domestic CCL enterprise. The agreement stipulates that Defu Sales will supply a minimum quantity of high-end electronic circuit copper foil products, including RTF1-4 and HVLP1-4系列, to the enterprise during 2026. This is considered a routine operating contract expected to positively impact the company's 2026 operating performance, fostering a long-term stable cooperative relationship and enhancing the company's position in the industrial chain.
4. Sanxia New Material announced its intention to acquire a 40% equity stake in Sanxia New Material Lingang New Material (Yichang) Co., Ltd. from Yichang State-owned Capital Investment Holding Group Co., Ltd. for a transaction price of RMB 0. This transaction constitutes a connected transaction but does not amount to a major asset reorganization. The company's board of directors and a special committee of independent directors have approved the transaction, which does not require submission to a shareholders' meeting for approval.
5. Fuling Precision announced that its subsidiary, Jiangxi Shenghua, plans to invest a total of RMB 8.7 billion in constructing projects including an annual production capacity of 500,000 tons of high-end energy storage-grade lithium iron phosphate (LFP). This includes an estimated investment of RMB 6 billion for the LFP project in the Yijin Huoluo Banner Mengsu Economic Development Zone. Additionally, Jiangxi Shenghua plans to build new projects in Wushen Banner for an annual output of 400,000 tons of a novel LFP precursor (oxalic acid project) with an estimated investment of RMB 1.2 billion, and an annual output of 600,000 tons of another novel LFP precursor (ferrous oxalate project) with an estimated investment of RMB 1.5 billion.
6. Hengrui Pharmaceuticals announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HRS9531 injection in combination with HRS-5817 injection for adult patients with obesity or overweight. HRS9531 is a novel双激动剂 targeting both the GLP-1 receptor and the GIP receptor, with global independent intellectual property rights. HRS-5817 is a self-developed Class 1 chemical drug that has demonstrated weight loss effects in obese animal models. Following approval, clinical trials must be conducted and subsequently reviewed and approved by the NMPA before the drugs can be produced and marketed.
7. Quartz Corp. announced that it and its controlling subsidiary, Lianyungang Qiangbang Quartz Products Co., Ltd., have received a criminal judgment from the Lianyungang Intermediate People's Court in Jiangsu Province. Qiangbang Company was found guilty of infringing trade secrets and sentenced to a fine of RMB 2.7 million. The company was the victim in this case, and Qiangbang's offense relates to facts prior to its acquisition by Quartz Corp. After the judgment takes effect, the company will pursue civil liability against relevant parties based on the Share Transfer Agreement. This is a first-instance judgment and is not yet final.
8. ST Renfu announced that its wholly-owned subsidiary, Hubei Bio-medical Industry Technology Research Institute Co., Ltd., recently received approval from the NMPA for clinical trials of HW221043 tablets as a monotherapy for patients with advanced solid tumors. HW221043 tablets are intended for the treatment of advanced solid tumors, and there are currently no同类药物approved for marketing domestically or internationally. Cumulative R&D investment for this drug amounts to approximately RMB 24 million. The subsidiary must now initiate clinical research and, upon completion, submit the data to the NMPA to apply for production and marketing approval.
9. Tianchen Medical announced that it has signed a strategic cooperation agreement with Inspur Digital Technology (Shanghai) Co., Ltd. on December 31, 2025. The collaboration aims to jointly promote the innovative application and industrialization of medical intelligence and information technology in areas such as the intelligent manufacturing of medical devices and consumables, and the R&D and production of medical robots. This agreement is a significant step in implementing the company's dual-engine strategy.
10. Xusheng Group announced that it has received a project designation from a North American new energy vehicle manufacturer to supply components including powertrain systems, body parts, subframes, and battery boxes. According to the customer's plan, the project has an estimated lifecycle of 8 years with total sales of approximately RMB 7.8 billion, and mass production is expected to commence by the end of 2026. Production will be located at the company's bases in China and Mexico. This designation deepens the long-term cooperation but does not guarantee final purchase volumes, as actual sales are subject to factors like the customer's production and market conditions.
11. Dengyun Co., Ltd. announced that its actual controller, Yang Tao, was arrested on December 25, 2025, by the Chaoyang Branch of the Beijing Public Security Bureau on suspicion of the crime of illegally absorbing public deposits. Yang Tao does not hold any position in the company, and this matter is not expected to significantly impact the company's governance or daily production and operations. The company will monitor developments and fulfill its information disclosure obligations.
12. Shengyang Technology, in an investor relations activity record announcement, stated that the South American project between its subsidiary FTA and a global leading satellite operator is progressing according to the contract. Initial phases involve software licensing, custom development, and small-batch delivery verification of terminal products. Subsequently, the company plans to leverage its partner's channel resources to gradually expand terminal product coverage in South America and explore synergies with local operators to achieve large-scale project implementation. FTA's core technological advantage lies in its DVB-NIP technology's bidirectional interaction capability for content distribution between satellite and IP networks.
13. Hefu China announced that its controlling shareholder, Hefu (Hong Kong) Limited, has reduced its stake by 3.98 million shares, representing 0.9999% of the company's total shares, through集中竞价trading, and has decided to terminate its减持plan ahead of schedule. This early termination is due to the shareholder's funding needs having been met and is intended to express confidence in and support for the company's future development.
14. Weigao Blood Purification announced that Weigao Co., Ltd. and its concerted actors plan to acquire 100% of the equity in Weigao Prunus through a share issuance. The assessed value of the target company's equity is RMB 8.511 billion. Upon completion of the transaction, the listed company's business scope will expand to include the R&D, production, and sales of pharmaceutical packaging materials such as pre-filled syringe drug delivery systems and automatic safe drug delivery systems. The controlling shareholders' combined stake in the listed company will be 84.36% post-transaction, not affecting its listed status.
**Trading Halts & Risk Warnings** Zhongtian Rocket: The company's carbon/carbon thermal field materials business has incurred losses due to intensified competition in the photovoltaic industry, significantly impacting the consolidated financial statements.
**Earnings Previews** 1. Sinoma Science & Technology Co.,Ltd.: Estimates 2025 net profit of RMB 1.55 billion - RMB 1.95 billion, a year-on-year increase of 73.79% - 118.64%. 2. Guangdong Dtech Technology Co.,Ltd.: Estimates 2025 net profit of RMB 410 million - RMB 460 million, a year-on-year increase of 81% - 103%. 3. Huayou Cobalt: Estimates 2025 net profit of RMB 5.85 billion - RMB 6.45 billion, a year-on-year increase of 40.80% to 55.24%. 4. Chifeng Gold: Estimates 2025 net profit of RMB 3.0 billion - RMB 3.2 billion, a year-on-year increase of approximately 70% - 81%. 5. Nanxing Co., Ltd. (3 consecutive limit-ups): Estimates 2025 net profit of RMB 90 million – RMB 120 million, compared to a loss of RMB 175 million in the previous year. 6. Whirlpool China: Estimates 2025 net profit of approximately RMB 505 million, an increase of about 150% year-on-year. 7. Lizhong Group: Estimates 2025 net profit of RMB 830 million - RMB 870 million, a year-on-year increase of 17.38% - 23.04%.
**Major Contract Awards** 1. Far East Co., Ltd.: Subsidiaries won project orders totaling RMB 3.069 billion in December. 2. China Merchants Energy Shipping: Signed a shipbuilding agreement for dynamic positioning shuttle tankers worth RMB 1.79 billion. 3. Qiaoyin Shares: Won a特许经营project for integrated urban-rural environmental sanitation services worth approximately RMB 1.225 billion. 4. Huakang Cleanliness: Won a procurement project for special hospital departments worth RMB 157 million.
**Share Buybacks & Stake Changes** 1. Pioneer Precision: Shareholder Youlijia Partnership plans to reduce its holding by no more than 3.00%. 2. Baichuan Energy: Controlling shareholder Baichuan Asset Management plans to reduce its holding by no more than 3%. 3. Hangya Technology: Shareholders plan to collectively reduce their holdings by no more than 2.76%. 4. Sunway Co., Ltd.: Shareholder Li Guangyuan plans to reduce his holding by no more than 1%.
Comments